Re: Resveratrol supplementation does not extend lifespan in ad libitum-fedrodents.
jc101 wrote:
>>BENEFITS OF RESVERATROL
>>Resveratrol use shows a significant effect on osteoporosis, cataracts,
>>locomotor function and vascular function ...
>>
>>François Rose
The Microsoft word document that I have referenced uses information like
that above to support it's study design.
>
>
> Persons who have been overdosing on resveratrol will now have to eat
> crow and back down on dosages. These are essentially 'plant derived
> poisons' and are used hormetically to stimulate the mammal. You can
> get too much.
>
> We have used for years 1/4 tsp of resveratrol extract and 1/4 tsp of
> fisetin extract. These run about 40-50% potency by our lab analysis,
> so around 250 mg of each chemical net; use with food.
> JLC
The following is a Microsoft Document and is the 3rd item listed at
http://tinyurl.com/636fb9:
Contract: NCI Division of Cancer Prevention N01-CN-25025-3
TASK 2 A
Phase I repeat-dose clinical study of safety, pharmacokinetics and
pharmacodynamics of resveratrol
Protocol Version 3.2
June 2, 2006 (This is a 75 page document, but not all of it needs to be
reviewed.)
It was basically a design for the protocol to use in human subjects. It
gives the rationale for the dosages of resveratrol to be used.
1.0 Objectives of Task 2A
1.1 Objective 1
Measure concentrations of resveratrol and its metabolites in the plasma,
urine and stool of humans, and establish resveratrol pharmacokinetics
after at least 20 days of dosing. Characterize changes in
pharmacokinetics between the first and last dose.
Hypothesis: Resveratrol given once daily at a dose of 1 gm for at least
20 days will generate a Cmax at steady state of 50 μM combined
resveratrol + glucuronide metabolites in 80% or more of human participants.
1.2 Objective 2
Establish the effect of a single dose and steady state concentrations of
resveratrol obtained after a minimum of 20 days of dosing on COX-2
activity and M1G concentration in circulating white blood cells,
compared to pre-dose.
Hypothesis: A Cmax steady state resveratrol + glucuronide
concentrations of 50 μM or greater at steady state after a minimum of 20
days of dosing will be sufficient to cause a 50% or more reduction in
Cox-2 activity in circulating white blood cells compared to pre-dosing.
Hypothesis: A resveratrol + glucuronide concentration of 50 μM or
greater at steady state after a minimum of 20 days of treatment will be
sufficient to cause a 60% or more reduction in M1G concentrations in
circulating white blood cells compared to pre-treatment.
1.3 Objective 3
To obtain a preliminary toxicity profile of resveratrol given at doses
up to 5 gm per day.
Hypothesis: A daily resveratrol of 5.0 gm given for 29 days will result
in less than 5% incidence of any grade 2 or greater NCI Common Toxicity
scale toxicity in healthy human participants.
In addition Siritis used 2.5 and 5 gram doses in a phase I trial in
India of type 2 diabetics to test resveratrols safety. They are doing a
phase II trial using the same doses plus metformin.
Also a clinical trial is being conducted by the University of California
San Francisco in subject with metabolic syndrome at 5 grams of
resveratrol per day - http://tinyurl.com/578zjp.
We should have more reliable information of resveratrol dosages and
safety in humans in the near future.
Frank
rjk3@my-deja.c…
ironjustice
